Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases.
Clin Immunol
; 194: 75-79, 2018 09.
Article
em En
| MEDLINE
| ID: mdl-30004016
ABSTRACT
There is no therapeutic agent approved in cutaneous mastocytosis and mast cell activation syndrome. We report the efficacy of hydroxychloroquine in four patients with cutaneous mastocytosis (nâ¯=â¯2) and mast cell activation syndrome (nâ¯=â¯2). We show that this molecule reduces the long-term survival of primary human mast cells, interferes with lysosome function and leads to the accumulation of non-functional tryptase in the mast cell granules. Furthermore, hydroxychloroquine decreases the production of pro-inflammatory mediators.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Mastocitose
/
Hidroxicloroquina
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Clin Immunol
Assunto da revista:
ALERGIA E IMUNOLOGIA
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
França